Iris Rajman

1.2k total citations
31 papers, 885 citations indexed

About

Iris Rajman is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Iris Rajman has authored 31 papers receiving a total of 885 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Cardiology and Cardiovascular Medicine, 7 papers in Endocrinology, Diabetes and Metabolism and 5 papers in Surgery. Recurrent topics in Iris Rajman's work include Heart Failure Treatment and Management (10 papers), Blood Pressure and Hypertension Studies (6 papers) and Pharmacogenetics and Drug Metabolism (4 papers). Iris Rajman is often cited by papers focused on Heart Failure Treatment and Management (10 papers), Blood Pressure and Hypertension Studies (6 papers) and Pharmacogenetics and Drug Metabolism (4 papers). Iris Rajman collaborates with scholars based in Switzerland, United States and United Kingdom. Iris Rajman's co-authors include Thomas Langenickel, Parasar Pal, Robert Cramb, Thomas M. Morgan, Collen Masimirembwa, M. J. Kendall, Surya Ayalasomayajula, Phil Chowienczyk, James M. Ritter and Magdi M. Salih and has published in prestigious journals such as Journal of the American College of Cardiology, PLoS ONE and Clinical Pharmacology & Therapeutics.

In The Last Decade

Iris Rajman

31 papers receiving 846 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Iris Rajman Switzerland 17 372 221 169 107 91 31 885
James J. Nawarskas United States 21 509 1.4× 111 0.5× 249 1.5× 128 1.2× 165 1.8× 65 1.1k
Nicolás Roberto Robles Spain 16 452 1.2× 218 1.0× 123 0.7× 125 1.2× 104 1.1× 142 1.1k
B. Frigerio Italy 13 376 1.0× 169 0.8× 212 1.3× 121 1.1× 75 0.8× 27 846
Gangadhar Sunkara United States 22 261 0.7× 237 1.1× 151 0.9× 118 1.1× 210 2.3× 71 1.0k
Eric Yang United States 21 622 1.7× 158 0.7× 225 1.3× 190 1.8× 201 2.2× 63 1.4k
Alan Jones United Kingdom 17 320 0.9× 272 1.2× 239 1.4× 68 0.6× 109 1.2× 36 928
Michael B. Bottorff United States 18 574 1.5× 150 0.7× 432 2.6× 100 0.9× 114 1.3× 67 1.4k
Oliver Jung Germany 15 419 1.1× 292 1.3× 147 0.9× 69 0.6× 231 2.5× 25 1.3k
Francesco Rozza Italy 16 545 1.5× 185 0.8× 119 0.7× 37 0.3× 90 1.0× 55 866
Juan Maya United States 18 907 2.4× 181 0.8× 446 2.6× 100 0.9× 78 0.9× 38 1.4k

Countries citing papers authored by Iris Rajman

Since Specialization
Citations

This map shows the geographic impact of Iris Rajman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iris Rajman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iris Rajman more than expected).

Fields of papers citing papers by Iris Rajman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iris Rajman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iris Rajman. The network helps show where Iris Rajman may publish in the future.

Co-authorship network of co-authors of Iris Rajman

This figure shows the co-authorship network connecting the top 25 collaborators of Iris Rajman. A scholar is included among the top collaborators of Iris Rajman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Iris Rajman. Iris Rajman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rajman, Iris, et al.. (2020). New paradigm for expediting drug development in Asia. Drug Discovery Today. 25(3). 491–496. 7 indexed citations
2.
Rajman, Iris, et al.. (2020). Genetic Diversity in Drug Transporters: Impact in African Populations. Clinical and Translational Science. 13(5). 848–860. 10 indexed citations
3.
Rajman, Iris, et al.. (2017). African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development. EBioMedicine. 17. 67–74. 88 indexed citations
4.
Kulmatycki, Kenneth, Thomas Langenickel, Dik Ng, et al.. (2017). Pharmacokinetics and safety of sacubitril/valsartan (LCZ696) in patients with mild and moderate hepatic impairment. International Journal of Clinical Pharmacology and Therapeutics. 55(9). 728–739. 8 indexed citations
5.
Ayalasomayajula, Surya, Mark S. Greeley, Parasar Pal, et al.. (2017). Evaluation of Pharmacokinetic and Pharmacodynamic Drug–Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild‐to‐Moderate Hypertension. Clinical Pharmacology & Therapeutics. 103(3). 468–476. 6 indexed citations
6.
Ayalasomayajula, Surya, Thomas Langenickel, Pierre J. Jordaan, et al.. (2016). Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor. European Journal of Clinical Pharmacology. 72(9). 1065–1073. 27 indexed citations
7.
Kotovskaya, Yu. V., О. В. Аверков, Е.П. Павликова, et al.. (2016). Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction. Cardiovascular Therapeutics. 34(4). 191–198. 66 indexed citations
8.
Langenickel, Thomas, John G. Roberts, Parasar Pal, et al.. (2015). Pharmacokinetic drug–drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol. Clinical Pharmacology in Drug Development. 4(6). 407–417. 21 indexed citations
9.
Dallmeier, Dhayana, Michael Pencina, Iris Rajman, et al.. (2015). Serial Measurements of N-Terminal Pro-Brain Natriuretic Peptide in Patients with Coronary Heart Disease. PLoS ONE. 10(1). e0117143–e0117143. 10 indexed citations
10.
Villevalde, S. V., Yu. V. Kotovskaya, Holger Hinrichsen, et al.. (2014). Pharmacokinetics of serelaxin in patients with hepatic impairment: a single‐dose, open‐label, parallel group study. British Journal of Clinical Pharmacology. 79(6). 937–945. 23 indexed citations
11.
Rothenbacher, Dietrich, Michael M. Hoffmann, Lutz Philipp Breitling, et al.. (2013). Cytochrome P450 2C19*2 polymorphism in patients with stable coronary heart disease and risk for secondary cardiovascular disease events: results of a long-term follow-up study in routine clinical care. BMC Cardiovascular Disorders. 13(1). 61–61. 4 indexed citations
12.
Thalamas, Claire, Iris Rajman, Jaime Kulisevsky, et al.. (2005). Pergolide. Clinical Neuropharmacology. 28(3). 120–125. 12 indexed citations
13.
Terra, Steven G., Robert A. Blum, Greg C. G. Wei, et al.. (2004). Evaluation of Methods for Improving Precision of Blood Pressure Measurements in Phase I Clinical Trials. The Journal of Clinical Pharmacology. 44(5). 457–463. 9 indexed citations
14.
McNeill, K., Luigi Fontana, David Russell‐Jones, et al.. (2000). Inhibitory effects of low-density lipoproteins from men with type II diabetes on endothelium-dependent relaxation. Journal of the American College of Cardiology. 35(6). 1622–1627. 25 indexed citations
15.
Rajman, Iris. (1998). Low-density lipoprotein subfraction profiles in chronic renal failure. Nephrology Dialysis Transplantation. 13(9). 2281–2287. 61 indexed citations
16.
Rajman, Iris, Gregory Y.H. Lip, Robert Cramb, et al.. (1996). Adverse change in low-density lipoprotein subfractions profile with oestrogen-only hormone replacement therapy. QJM. 89(10). 771–778. 12 indexed citations
17.
Rajman, Iris, M. J. Kendall, Robert Cramb, et al.. (1996). Investigation of low density lipoprotein subfractions as a coronary risk factor in normotriglyceridaemic men. Atherosclerosis. 125(2). 231–242. 91 indexed citations
18.
Kendall, M. J. & Iris Rajman. (1994). A Risk-Benefit Assessment of Celiprolol in the Treatment of Cardiovascular Disease. Drug Safety. 10(3). 220–232. 4 indexed citations
19.
Kendall, M. J., Iris Rajman, & Simon Maxwell. (1994). Cardioprotective therapeutics—drugs used in hypertension, hyperlipidaemia, thromboembolism, arrhythmias, the postmenopausal state and as anti-oxidants. Postgraduate Medical Journal. 70(823). 329–343. 5 indexed citations
20.
Rajman, Iris, Simon Maxwell, Robert Cramb, & M. J. Kendall. (1994). Particle size: the key to the atherogenic lipoprotein?. QJM. 87(12). 709–720. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by James J. Nawarskas Breakdown of academic impact, for papers by Nicolás Roberto Robles Breakdown of academic impact, for papers by B. Frigerio Breakdown of academic impact, for papers by Gangadhar Sunkara Breakdown of academic impact, for papers by Eric Yang Breakdown of academic impact, for papers by Alan Jones Breakdown of academic impact, for papers by Michael B. Bottorff Breakdown of academic impact, for papers by Oliver Jung Breakdown of academic impact, for papers by Francesco Rozza Breakdown of academic impact, for papers by Juan Maya
Rankless by CCL
2026